Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.

ABSTRACT: Several biomarkers such as tumor mutation burden (TMB), neoantigen load (NAL), programmed cell-death receptor 1 ligand (PD-L1) expression, and lactate dehydrogenase (LDH) have been developed for predicting response to immune checkpoint inhibitors (ICIs) in melanoma. However, some limitations including the undefined cut-off value, poor uniformity of test platform, and weak reliability of prediction have restricted the broad application in clinical practice. In order to identify a clinically actionable biomarker and explore an effective strategy for prediction, we developed a genetic mutation model named as immunotherapy score (ITS) for predicting response to ICIs therapy in melanoma, based on whole-exome sequencing data from previous studies. We observed that patients with high ITS had bett

SUBMITTER: Jiang J 

PROVIDER: S-EPMC7666739 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature